Logo

Compugen Reports $281K Q1 Revenues

May 14, 2008
NEW YORK (GenomeWeb News) – Compugen today reported first-quarter revenues of $281,000 versus no revenues in the comparable period a year ago.
 
The Tel Aviv, Israel-based developer of predictive drug discovery platforms posted a net loss of $2.5 million, or $.09 per share, down 19.4 percent from a net loss of $3.1 million, or $.11 per share, for the first quarter of 2007.
 
Compugen’s R&D expenses decreased 10 percent to $1.8 million from $2 million, and its SG&A costs increased 9 percent to $1.2 million from $1.1 million.
 
The firm held cash, cash equivalents, deposits, and marketable securities of $14.8 million as of March 31.

Breaking News
The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.